company background image
INSM

Insmed NasdaqGS:INSM Stock Report

Last Price

US$20.89

Market Cap

US$2.5b

7D

-2.5%

1Y

-26.7%

Updated

03 Jul, 2022

Data

Company Financials +
INSM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

INSM Stock Overview

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.

Insmed Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Insmed
Historical stock prices
Current Share PriceUS$20.89
52 Week HighUS$34.44
52 Week LowUS$16.41
Beta2.07
1 Month Change13.29%
3 Month Change-14.63%
1 Year Change-26.70%
3 Year Change-16.17%
5 Year Change20.96%
Change since IPO-87.34%

Recent News & Updates

Jun 24
Is Insmed (NASDAQ:INSM) A Risky Investment?

Is Insmed (NASDAQ:INSM) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

INSMUS BiotechsUS Market
7D-2.5%0.07%-2.5%
1Y-26.7%-25.1%-21.2%

Return vs Industry: INSM underperformed the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: INSM underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is INSM's price volatile compared to industry and market?
INSM volatility
INSM Average Weekly Movement10.1%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.3%

Stable Share Price: INSM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: INSM's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1988613Will Lewishttps://www.insmed.com

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.

Insmed Fundamentals Summary

How do Insmed's earnings and revenue compare to its market cap?
INSM fundamental statistics
Market CapUS$2.50b
Earnings (TTM)-US$437.63m
Revenue (TTM)US$201.35m

12.4x

P/S Ratio

-5.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
INSM income statement (TTM)
RevenueUS$201.35m
Cost of RevenueUS$46.50m
Gross ProfitUS$154.86m
Other ExpensesUS$592.49m
Earnings-US$437.63m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.66
Gross Margin76.91%
Net Profit Margin-217.35%
Debt/Equity Ratio653.3%

How did INSM perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is INSM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for INSM?

Other financial metrics that can be useful for relative valuation.

INSM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue13.3x
Enterprise Value/EBITDA-7.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does INSM's PS Ratio compare to its peers?

INSM PS Ratio vs Peers
The above table shows the PS ratio for INSM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average6.2x
FOLD Amicus Therapeutics
9.5x25.1%US$3.0b
PTCT Therapeutics
5.2x10.6%US$3.0b
ACAD ACADIA Pharmaceuticals
4.7x27.9%US$2.3b
NTRA Natera
5.3x18.3%US$3.6b
INSM Insmed
12.4x40.4%US$2.5b

Price-To-Sales vs Peers: INSM is expensive based on its Price-To-Sales Ratio (12.4x) compared to the peer average (6.2x).


Price to Earnings Ratio vs Industry

How does INSM's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: INSM is good value based on its Price-To-Sales Ratio (12.4x) compared to the US Biotechs industry average (13.2x)


Price to Sales Ratio vs Fair Ratio

What is INSM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

INSM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio12.4x
Fair PS Ratio13.2x

Price-To-Sales vs Fair Ratio: INSM is good value based on its Price-To-Sales Ratio (12.4x) compared to the estimated Fair Price-To-Sales Ratio (13.2x).


Share Price vs Fair Value

What is the Fair Price of INSM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate INSM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate INSM's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate INSM's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Insmed forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


48.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: INSM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INSM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INSM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INSM's revenue (40.4% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: INSM's revenue (40.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if INSM's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Insmed performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-14.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: INSM is currently unprofitable.

Growing Profit Margin: INSM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: INSM is unprofitable, and losses have increased over the past 5 years at a rate of 14.3% per year.

Accelerating Growth: Unable to compare INSM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INSM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).


Return on Equity

High ROE: INSM has a negative Return on Equity (-365.06%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Insmed's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: INSM's short term assets ($756.1M) exceed its short term liabilities ($125.2M).

Long Term Liabilities: INSM's short term assets ($756.1M) do not cover its long term liabilities ($908.2M).


Debt to Equity History and Analysis

Debt Level: INSM's net debt to equity ratio (123.5%) is considered high.

Reducing Debt: INSM's debt to equity ratio has increased from 45.4% to 653.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INSM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: INSM has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 16.2% each year.


Discover healthy companies

Dividend

What is Insmed current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate INSM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INSM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INSM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INSM's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as INSM has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Will Lewis (53 yo)

9.83yrs

Tenure

US$7,322,642

Compensation

Mr. William H. Lewis, also known as Will, J.D., M.B.A., has been Chief Executive Officer and President at Insmed Incorporated since September 11, 2012 and has been its Chairman of Board since November 6, 2...


CEO Compensation Analysis

Compensation vs Market: Will's total compensation ($USD7.32M) is about average for companies of similar size in the US market ($USD6.91M).

Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: INSM's management team is considered experienced (2.9 years average tenure).


Board Members

Experienced Board: INSM's board of directors are considered experienced (8.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: INSM insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.9%.


Top Shareholders

Company Information

Insmed Incorporated's employee growth, exchange listings and data sources


Key Information

  • Name: Insmed Incorporated
  • Ticker: INSM
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$2.497b
  • Shares outstanding: 119.52m
  • Website: https://www.insmed.com

Number of Employees


Location

  • Insmed Incorporated
  • 700 US Highway 202/206
  • Bridgewater
  • New Jersey
  • 8807
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/03 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.